Article

De-escalating Treatment Strategies for Patients with Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Early-Stage Breast Cancer

2024-09-05

Abstract excerpt

Almost one fifth of breast cancer cases express Human Epidermal Growth Factor-2 (HER2), and such expression is associated with highly proliferative tumor and poor prognosis. The introduction of anti-HER2 therapies has dramatically changed the natural course of this aggressive subtype of breast cancer. However, anti-HER2 therapy can be associated with substantial toxicities, mostly cardiac, and high cost. Over the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: de9df8f3-4586-5ba4-887a-608090fcf709
DOI: 10.20944/preprints202409.0327.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

De-escalating Treatment Strategies for Patients with Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Early-Stage Breast CancerDOI 10.20944/preprints202409.0327.v1Read

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistanceSemantic proximity Read

Facts and controversies in the use of trastuzumab in the adjuvant setting.Semantic proximity Read

The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.Semantic proximity Read

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.Semantic proximity Read

Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer.Semantic proximity Read

Clinical Impact of Interruption in Adjuvant Trastuzumab Therapy in Patients with Operable HER-2 Positive Breast CancerSemantic proximity Read

Translating neoadjuvant therapy into survival benefits: one size does not fit all.Semantic proximity Read

Advanced hormone-sensitive breast cancer: overcoming resistance.Semantic proximity Read

Evolving treatment strategies for triple-negative breast cancer.Semantic proximity Read

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.Semantic proximity Read

Switching ahead of progression: Insights from the SERENA-6 trial on targeting emerging ESR1 mutations in advanced HR+/HER2- breast cancer.Semantic proximity Read

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china.Semantic proximity Read